Stavudine adverse reactions: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) No edit summary |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| Line 8: | Line 8: | ||
*:[[lactic acidosis]] and severe [[hepatomegaly]] with steatosis | *:[[lactic acidosis]] and severe [[hepatomegaly]] with steatosis | ||
*:[[Hepatic toxicity]] | *:[[Hepatic toxicity]] | ||
*:Neurologic symptoms and motor weakness | *:Neurologic symptoms and motor weakness | ||
*:[[Pancreatitis]] | *:[[Pancreatitis]] | ||
*:[[lipoatrophy]]/[[lipodystrophy]] | *:[[lipoatrophy]]/[[lipodystrophy]] | ||
Revision as of 07:13, 3 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Adverse Reactions
The following adverse reactions are discussed in greater detail in other sections of the labeling:
- lactic acidosis and severe hepatomegaly with steatosis
- Neurologic symptoms and motor weakness
When ZERIT is used in combination with other agents with similar toxicities, the incidence of adverse reactions may be higher than when stavudine is used alone.[1]
References
Adapted from the FDA Package Insert.